1. What is €5 billion worth?
Magda Gunn, IMI Scientific Project Manager

2. Drug discovery is complex

3. Key concepts Focus on unmet needs Competitive Calls for proposals
Open collaboration in public-private consortia
Data sharing, dissemination of results…
Industry contribution is in kind
A partnership between EU Commission and the European Federation of Pharmaceutical Industries and Association (EFPIA)

4. PATIENTS’ ORGANISATIONS SMALL AND MEDIUM-SIZED ENTERPRISES
Typical IMI project
Industry
ACADEMIA
HOSPITALS
PATIENTS’ ORGANISATIONS
SMALL AND MEDIUM-SIZED ENTERPRISES
REGULATORS
Pharma 1
Pharma 2
Pharma 3
Pharma 4
Pharma 5
Pharma 6
Private
Investment
in kind
EU Public
Funding
cash 4

5. Many stakeholders many expectations

6. 2.7 billion remaining 17 2.6 billion committed 68 Calls for proposals
projects

7. Performance monitoring framework
Scientific output
Impact on drug development
Impact on regulatory framework
Business opportunities and sustainability
Socio-economic impact
Information, communication and dissemination

8. Scientific Output

9. IMI scientific output 24% Highly cited 1134 2.19 citation impact 9359
publications
2.19 citation impact
9359
citations
376
224

10. Benchmarking

11. Collaboration delivers excellence
International
collaboration
50% of IMI publications
Collaboration between sectors 61%
of IMI publications
collaboration between institutions
75% of IMI publications
Data & analysis: Thomson Reuters (Custom Analytics & Engineered Solutions)

12. Tracking collaborations across EU
Co-authorship between IMI-supported researchers Calls 1-4
Pre IMI funding award
Post IMI funding award
Data & analysis: Thomson Reuters (Custom Analytics & Engineered Solutions)

13. Securing regulatory relevance

14. Securing regulatory relevance
New standards and best practices derived from IMI projects
Number of scientific advice and qualified opinions initiated by the IMI projects at the EMA and FDA
Number of regulatory guidelines derived from IMI projects

15. Business development and sustainability

16. IMI project patenting trends
20 patent applications
3.2 patents per €10 million of costs accepted by IMI
Target for H2020 is ≥ 2 per €10 million of costs accepted by IMI

17. Business relevant outputs (n=50)
Spin-offs breakdown
New Projects
Companies & joint ventures
Foundations & non-profits

18. Job creation as a result of IMI projects
2 272 direct jobs created
indirect jobs* *

19. Key stakeholder involvement

20. Promoting SME participation
SMEs receive 18% of IMI funding
15% of IMI participants are SMEs
Thanks to IMI the company went from 6 to 50 employees.
Now they are ready to further expand.
“1st product released to the market in 2013 – IMI was instrumental in validation of the first cell line product, 2nd product release planned this year, 3rd diagnostic product in development.
In preparation: a new patent filing to protect technologies for the creation of third generation human beta cell lines.

21. Conclusions
A mix of quantitative indicators and qualitative assessment is needed to fully address the “So what?” question
Need to address criteria relevant to both public and corporate worlds is a challenge
Evaluation framework needs to incentivize desired outcomes and be the basis of a reward system
Long term impact measures still remain challenging.

22. Thank you!